Breaking News

  1. PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. This is a key step towards clinical testing for the treatment of chronic pain states. The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins and, in preclinical testing, it has none of the unwanted side effects of conventional opioid analgesics.PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. This is a key step towards clinical testing for the treatment of chronic pain states. The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins and, in preclinical testing, it has none of the unwanted side effects of conventional opioid analgesics.